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Despite total hip replacement (THR) gives generally satisfactory results, the quality of outcome in young patients is markedly decreased
compared to the average THR outcome. For this population, pharmacological treatment with bisphosphonate would be beneficial to decrease
the peri-implant osteolysis. However, as this population does not necessarily suffer from osteoporosis, a nonsystemic treatment would be
preferable. Zoledronate was then grafted to hydroxyapatite (HA) coating of titanium implants. The implants were inserted in rat condyles
with various zoledronate concentrations. A positive concentration-dependent effect was observed on the peri-implant bone density and on
different histomorphometric parameters. Importantly for the outcome of the implants, the mechanical fixation was increased by the local
presence of zoledronate.
The obtained results open the way of an easy transformation of currently existing HA-coated implants by grafting bisphosphonate onto the
coating in order to increase their service life in the patients.
D 2004 Elsevier Inc. All rights reserved.
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Introduction interface, while the migration of HA-coated acetabular cupsThe hydroxyapatite (HA) coating has been used now in
orthopedic surgery for over 15 years in cementless joint
replacement [10]. Initially, it was developed to accelerate
the peri-implant bone formation and thus decrease the time
needed to obtain a secondary fixation of the implant. The
initial fixation of the implant is crucial for the success of an
implant [27]. Since then, it has been shown that the HA
coating improves the stability of the implant, the interface
strength, the bone mineralization, and the bone ingrowth
rate [38]. Specifically, Adler et al. [1] showed that HA
coating increased the fatigue resistance of the bone–implant8756-3282/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.bone.2004.10.004
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ever, the interface between the coating and the implant may
become the weak point of the system [31]. This problem
was solved by decreasing the HA coating thickness [41].
As shown in the Swedish National Hip Arthroplasty
Register (SNHAR), cementless hip replacement survival is
as low as 75% in young patients after 10 years. Recently,
one way that was suggested to increase the lifetime of such
implants, was to use bisphosphonate [37]. The basic idea
was to decrease the primary failure mode which is aseptic
loosening following peri-implant osteolysis [14]. These
drugs are already successfully used in the treatment of
osteoporosis [12]. Bisphosphonates, such as ibandronate
[11], EDPH [32], zoledronate [3], TRK-530 [19], and
alendronate [43], have been extensively studied and
demonstrated their antiresorptive effect.5) 52–60
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by oral administration or intravenous injection. Different
studies have shown the positive effect of systemic
bisphosphonate treatment in protecting the peri-implant
bone, either around cemented [15] or around uncemented
implants [42]. However, side effects like fever [29,40],
throat, or stomach ulcers [9] as well as a low bioavailability
[16] are generally observed for systemic bisphosphonate
treatment. In order to avoid these adverse effects and to
increase the bisphosphonate bioavailability, the systemic
treatment following a total hip replacement (THR) could be
replaced by a local delivery with the implant selectively
coated with bisphosphonate. The bone in contact with the
implant will be the only part of the skeleton being exposed
to the drug. This is important as patients undergoing THR
do not necessarily present osteoporosis.
Few studies have tried to evaluate the effect of local
bisphosphonate delivery with implant. The local drug
delivery approach has been tested in vivo with no negative
effects but only slight increase in implant osteointegration
for dental implants [25,26] or for bulk hydroxyapatite
blocks [7,8]. Recently, Yoshinari et al. [44] used plasma-
sprayed HA-coated titanium dental implant which were
immersed in pamidronate and implanted in beagle man-
dibular bone. This study showed a 10% increase in bone
contact area. Tengvall et al. [39] showed a 28% increase in
pullout force and 90% pullout energy when comparing
stainless steel screws with the same type of screws but
coated with a fibrinogen coating containing pamidronate
and implanted in rat tibia. In the limit of our knowledge, no
information can be found about the optimal bisphosphonate
quantity needed to achieve an increase specifically in
fixation of orthopedic implant.
We aim at determining whether zoledronate locally
released from an HA-coated implant could increase the
mechanical fixation of metallic implant in bones. Therefore,
the study explores the zoledronate concentration range to
determine which concentration leads to the optimal bone
density distribution around the implant, optimal distribution
being defined as the distribution that leads to the highest
mechanical stability of the implant as determined by the
maximal pullout force. Moreover, the changes in the bone
structure were also assessed using histomorphometric
measurements.Table 1
Number of rats per condition and femurs (slices) per test
Conditions Rats SEM Histomorphometry Pullout
Control 4 3 (18) 3 (18) 2
0.2 Ag/implant 4 2 (28) 2 (28) 1
2.1 Ag/implant 4 4 (32) 4 (32) 3
8.5 Ag/implant 4 4 (33) 4 (33) 4
16 Ag/implant 4 4 (21) 4 (21) 3Materials and methods
Animals
Twenty female 6-month-old Wistar rats were used for
this experiment. The rats are all mature. The animals had
free access to normal diet. The animals were randomly
separated in five groups representing the different zoledro-
nate concentrations in the HA coating: 0, 0.2, 2.1, 8.5, and
16 Ag/implant.The column bRatsQ in Table 1 shows the number of rats
implanted for this study. Three rats belonging to different
groups died of causes unrelated to the study. Each rat
received two implants containing the same zoledronate
concentration, one in each condyle. For each animal, one
condyle was used for density measurement and histomor-
phometric measurements, while the contralateral condyle
was used for the pullout test. The columns bSEMQ and
bHistomorphometryQ in Table 1 give the number of femurs
used for these tests, and in parenthesis, the total number of
slides obtained. The column bPulloutQ gives the number of
condyles tested for each condition. Some femurs could not
be used for the pullout test because the condyles were
damaged during tissue removal.
Metal implants and zoledronate
Titanium alloy (TA6V) cylinders (diameter 3 mm; length
5 mm) were plasma-coated with hydroxyapatite (thickness:
20 Am; crystallinity index 62%).
Zoledronate (1-hydroxy-2-[(1H-imidazole-1-yl)ethyli-
dene] 1-bisphosphonic acid disodium salt) was supplied
by Novartis Pharmaceuticals AG, Basel, Switzerland.
Grafting of zoledronate
The chemical association of zoledronate with the HA
coating was carried out by soaking the implants in
zoledronate solution in ultrapure water. No stirring of the
reaction vessel was performed to prevent any mechanical
erosion of the HA coating. Typically, 19 implants were
immersed for 48 h in 5 ml of aqueous zoledronate
solutions of variable concentration: 2.25 106, 2.25 105,
2.25 104, and 2.25 103 mol l1, leading to modified
coatings. Then, the remaining amount of zoledronate in the
supernatant at the end of the reaction was determined as
previously described [20], using a protocol based on the
Ames method [2] for the determination of the phosphorus
content in solution. By difference with the initial amount
of zoledronate present in solution, the zoledronate loading
onto the implants was deduced, namely, 1.9–2.4 Ag
zoledronate per implant (corresponding to a full incorpo-
ration of zoledronate), 8–9 Ag zoledronate per implant
(corresponding to a 35% incorporation ratio), and 16 Ag
zoledronate per implant (corresponding to a 7% incorpo-
ration ratio). All the zoledronate-association experiments
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to the detection limit of our method, the zoledronate
loading for the lowest grafting concentration could not be
measured. Taking account of the data described above,
however, it is reasonable to assume that zoledronate was
quantitatively incorporated, with a value of 0.2 Ag per
implant. The presence of zoledronate on the modified
implants was investigated in the case of the coating loaded
with 16 Ag/implant; for that purpose, the calcium
phosphate coating was removed from the implant, and a
solid state 31P CP-MAS NMR spectrum of the resulting
powder clearly showed a weak signal in the expected
range for zoledronate (10–20 ppm), along with the
resonance corresponding to the calcium phosphate (2.7
[strong] and 6 [weak] ppm). Using an SEM, no alteration
of the coating due to the grafting process could be
measured.
Surgical protocol
The protocol for the animal experiment was approved
by the local Ethical Committee for Animal studies of
the National Veterinary School of Nantes. Animals were
kept at the Experimental Surgery Laboratory of the
Nantes University according to European Community
guidelines for the care and use of laboratory animals
(DE86/609/CEE).
Surgical procedures were conducted under general
anesthesia using intraperitoneal injection of sodium thio-
pental associated with subcutaneous injection of morphine
sulfate. Bilateral implantations were performed at the distal
end of the femurs, at the epiphysometaphyseal junction.
After lateral arthrotomy of the knee joint, the lateral
condyle was exposed and drilled perpendicularly to the
long axis of the femur. The drilling procedure was
performed with two successive bits (2.2 and 2.8 mm in
diameter) on a low-speed rotative dental handpiece and
under sterile saline irrigation. Hemostasis of the bone
cavity was controlled with sterile gauges, and the coated
implant was then gently inserted into the cavity under
digital pressure. The surgeon was blinded for the treat-
ment. Articular and cutaneous tissues were closed in two
separate layers. After surgery, all the animals were allowed
to move freely in their cages.
Animals were killed 3 weeks after implantation by
intracardiac injection of overdosed sodium pentobarbital,
after induction of intraperitoneal general anesthesia. Using a
A-CT, it was established that the position of the implant in
the condyle was similar for all animals.
SEM sample preparation
The femoral ends were then immediately dissected,
fixed in glutaraldehyde solution, and stored in a 4%
paraformaldehyde, 0.1% glutaraldehyde in 0.08 M caco-
dylate buffer.Using a handpiece, the condyle was sawed off 1 cm
above the implant. The sample was dehydrated in a series of
alcohol solutions. The first impregnation step was to soak
the sample in a mixture of 50% alcohol 1008 and 50%
methyl methacrylate MMA (Fluka Chemika, Sigma Aldrich
Chemie Gmbh, Steinheim, Germany) during 24 h. The
second impregnation step was to soak the sample in pure
MMA during 24 h.
The first inclusion step was to soak the dehydrated
sample during 2 h under vacuum in a solution containing
90% MMA, 10% dibutylphtalate (Fluka Chemika) and 1%
benzoyl peroxide (Fluka Chemika). The sample was then
removed from the solution and soaked in the same solution
but enhanced by a polymerization activator (N,N-dimethyl-
p-toluidine) (Fluka Chemika). The polymerization took
place at 208C and was complete after 48 h.
The samples were cut in slices 100 Am thick using a
Microtome saw 1600 (Leica, Nussloch, Germany) dia-
mond saw. The cutting plane was perpendicular to the
implant.
SEM
The slices were carbon-coated. The samples were then
observed in a JEOL JSM 6300 scanning electron micro-
scope (JEOL, Tokyo, Japan) using the backscattered
electron detector allowing to distinguish mineralized bone
from soft tissue. Each sample was observed at two different
magnifications: 10 and 23. These two magnifications
were chosen to assess the influence of the biocoating close
to the implant and further away.
Using Quantimet (Zeiss, Jena, Germany), the bone
density and bone surface were measured as a function of
the distance from the surface of the implant up to a distance
of 200 Am on the pictures taken at a magnification of 23.
By surface of the implant means the external side of the
coated titanium cylinder. The bone density is defined as the
ratio of the white surface of the examined area divided by
the total surface of the examined area.
Histomorphometry
A number of histomorphometric parameters have been
measured, and the following parameters [6] were influ-
enced by the biocoating: mean length of terminus-to-
terminus struts (Tm.Tm/TSL), mean length of node-to-
terminus struts (Nd.Tm/TSL), node to termini ratio
(Nd.Tm), mean length of node to node struts (Nd.Nd/
TSL), number of termini in the calcified skeleton (N.Tm),
and total strut length (TSL). The calculations were
performed using a home-written procedure with Quantimet
(Zeiss) language and are described by Chappard et al. [6].
The trabecular bone at depth between 1 and 4 mm was
used to calculate the histomorphometric parameters. The
parameters were calculated as a function of zoledronate
concentration.
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After careful removal of all tendons and other soft tissues
around the emerging part of the implant, a mould was made
out of PMMA for each bone, in order to evenly distribute
the stresses and so safely pull out the implant from the
condyle.
Pullout test
A tensile testing machine (Instron, Canton, USA)
equipped with a 1000-N gauge was used. The implants
were pulled with a steady speed of 1 mm/min. Displacement
versus force was registered and used for the determination
of the maximal pullout force.
Statistics
The number of slices per animal were accounted for as
repetition of the density measurement of the same animal.
One-way ANOVA and Fisher test were used to determine
the statistical significance of differences in the results. A
probability value of P V 0.05 was considered to be
statistically significant.Fig. 1. SEM pictures of two implanted condyles at magnification of 10
and 23. Panel a shows the bone structure of a condyle implanted with a
coated implant containing no zoledronate, and panel b shows the bone
structure of the condyle containing an implant coated with HA grafted with
2.1 Ag of zoledronate. The same implants and their peri-implant bone are
shown in panels c and d for the coatings loaded with 0 Ag and 2.1 Ag of
zoledronate, respectively, at a magnification of 23.Results
The SEM pictures shown in Fig. 1 clearly illustrate
from a qualitative point of view the positive effect of
zoledronate HA-coated implants on the peri-implant bone
density. Figs. 1a and b show the peri-implant bone
distribution around the implant HA-coated either non-
grafted with zoledronate or grafted with 2.1 Ag, respec-
tively. Figs. 1c and d show a more detailed view of the
peri-implant bone without or with zoledronate, respec-
tively. The bone density around the implant containing 2.1
Ag of zoledronate is clearly higher and localized in the
vicinity of the implant.
Fig. 2 shows the bone density as a function of
zoledronate concentration in the coating and the distance
from the surface of the implant. In the first 20 Am around
the implant, three behaviors can be observed. First, the two
lowest zoledronate concentrations (0.2 and 2.1 Ag/implant)
result in the highest bone densities with a steep decrease
with increasing distance from the implant, but still above
all the other cases (P b 0.01). Second, the implant loaded
with 8.5 Ag/implant shows a lower (P b 0.02) but steadier
density than the two cases described above. Third, the
bone density around the implant either loaded with the
highest zoledronate concentration (16 Ag/implant) or the
implant without zoledronate shows the lowest density.
These two cases are statistically not different from each
other. Nevertheless, these two cases follow different trends.
Bone density around the implant without zoledronate is
decreasing, while the bone density around the implantcontaining 16 Ag/implant zoledronate is increasing as a
function of distance.
Between 40 and 80 Am, the situation changes. The
highest bone density is obtained with an intermediate
zoledronate concentration (2.1 Ag/implant). The bone
around the implant loaded with 0.2 Ag/implant becomes
less dense than the bone around the implant loaded with
8.5 Ag/implant, thus inverting the situation observed closer
to the implant. The implant without any zoledronate
induces the lowest density (P b 0.01), about 30% lower
than the lowest bone density obtained with the zoledro-
nate-loaded implants. The implant containing the highest
zoledronate concentration constantly increases the bone
density which reaches the same density as the bone around
the implant containing 0.2 Ag/implant.
From 80 to 200 Am, the bone density around the
coatings containing zoledronate from 2.1 to 16 Ag/implant
converges to a common density comprised between 0.62
and 0.64. The zoledronate-free implants induce a constant
relative bone density of 0.35 which is statistically different
from the zoledronate-containing cases (P b 0.01). The
density of the bone growing around the coatings contain-
ing 0.2 Ag zoledronate is constant at 0.52 and statistically
Fig. 3. Pullout force as function of zoledronate concentration (mean F
SEM). At low zoledronate concentrations, the pullout force increases with
increasing zoledronate content of the coating. The pullout force reaches a
maximum with a zoledronate content of 2.1 Ag/implant. By further
increasing the zoledronate content of the coating, the pullout force
decreases and reaches levels lower than when no zoledronate is present.
Fig. 2. Bone density as function of condition (Ag/implant) and distance from implant surface (mean F SEM). Close to the implant, the peri-implant bone
density is the highest when 0.2 and 2.1 Ag of zoledronate are present in the coating. When higher zoledronate quantities are present in the coating, the density
decreases until reaching the same level as when no zoledronate is present. At 200 Am from the implant, the peri-implant bone density is the highest when 2.1 to
16 Ag zoledronate are present in the coating. An intermediate density level is obtained with 0.2 Ag/implant, while the lowest density is reached when no
zoledronate is present.
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(P b 0.028).
The maximal pullout force (Fig. 3) increases with
increasing zoledronate concentration up to 2.1 Ag/implant.
At higher doses, the maximal pullout force decreases with
increasing zoledronate concentration. Statistically, the coat-
ing containing 2.1 Ag zoledronate reaches a significantly
higher pullout force than the case containing 8.5 Ag (P =
0.02) and the case containing 16 Ag (P = 0.023). Due to low
number of specimens tested, no statistical difference could
be shown between the other cases.
Zoledronate presence influences four histomorphomet-
ric parameters (Tm.Tm/TSL, Nd.Tm/TSL, Nd.Nd/TSL,
total strut length) in a concentration-dependent manner,
while two parameters (Nd.Tm and N.Tm) are influenced
only by one concentration (Fig. 4). Tm.Tm/TSL, Nd.Tm/
TSL, and Nd.Nd/TSL are decreasing with increasing
zoledronate concentration. Statistically two groups
become visible: at concentrations of 0.2 and 2.1 Ag/
implant, the parameters are close to control, while at
higher zoledronate concentrations, Tm.Tm/TSL, Nd.Tm/
TSL, and Nd.Nd/TSL are lower.
TSL significantly increases with increasing zoledronate
concentration. TSL of the bone exposed to 0.2 Ag/implant
is not statistically different from the case without
zoledronate.
The parameters Nd.Tm and N.Tm show a different
profile. In both cases, the values for the bone treated with
0.2 Ag/implant are statistically different from all the other
cases (P b 0.019).Using a power law to fit the different histomorphometric
parameters with the pullout maximum force, we obtained the
correlation factors shown in Table 2. The parameters N.Tm
and Nd.Tm did not show any correlation with the maximum
pullout force (R2 of 0.22 and 0.21, respectively). TSL,
Fig. 4. Histomorphometric parameters as function of conditions (mean F SEM). Four parameters are dose-dependently influenced by zoledronate. Tm.Tm/
TSL, Nd.Tm/TSL, and Nd.Nd/TSL are decreased by increasing zoledronate concentration. TSL is increased with the zoledronate content of the coating. Nd.Tm
and N.Tm are only influenced by the coating containing 0.2 Ag/implant.
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correlated to the maximum pullout force (R2 of 0.87, 0.92,
0.92, and 0.86, respectively).Discussion
The goal of this study was to determine the zoledronate
concentration leading to an optimal peri-implant boneTable 2
Correlation factor of the histomorphometric parameters data fitted with the
maximum pullout force by a power law
Parameter R2
N.Tm 0.22
Nd/Tm 0.21
TSL 0.87
Nd.Nd/TSL 0.92
Nd.Tm/TSL 0.92
Tm.Tm/TSL 0.86density distribution, optimal from the point of view of
implant fixation. The most remarkable result of this study
was to show the existence of a window of zoledronate
concentration (0.2 to 2.1 Ag/implant) in which the mechan-
ical fixation of the implant is increased.
Tengvall et al. [39] showed an increase by 28% of the
pullout force of steel screws inserted in rat femurs by using
a fibrinogen/pamidronate/ibandronate coating. In the present
study, the implants containing 2.1 Ag of zoledronate induced
an increase in pullout force up to 42% compared to implants
without zoledronate. This difference may be explained by
the fact that zoledronate is more efficient in shifting the
bone remodeling towards a positive balance than the
bisphosphonates used by Tengvall et al. The combination
of HA and zoledronate is probably more favorable than
fibrinogen and bisphosphonate in the point of view of
orthopedic implant fixation.
At higher zoledronate concentrations, the pullout force
decreased by 35% when compared to implants without
zoledronate. The decrease in mechanical stability of the
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might be correlated to the lower mineralized bone density
close to the implant. Indeed, two situations are possible to
explain the lower mineralization, either impairment of the
mineralization itself or negative effect on osteoblast
function. In this study, the bone mineral density was
measured by detecting backscattered electrons using an
SEM. As shown by some others [5,35], this methods allows
to measure the bone mineralization. However, it was not
possible to determine if mineralization itself was impaired
by the presence of zoledronate. In a previous study, it has
been shown that alendronate has only small effects on the
bone mineralization [13]. This might also be the case for
zoledronate, but no conclusion can be obtained with the
present study. However, high zoledronate concentrations
may impair mineralization by affecting osteoblast function
as suggested in previous in vitro studies [33,34].
A supporting observation to this hypothesis is the fact
that in the first 20 Am around the implant, the bone density
is the same for the coating without zoledronate and the one
containing the highest zoledronate quantity. Moreover, with
increasing distance, the bone density around the implant
loaded with the highest zoledronate concentration increases,
whereas the bone density in case of zoledronate-free
implants decreases. This behavior of the zoledronate-
containing implant is due to the dilution of the zoledronate
with increasing distance. The abovementioned hypothesis
also explains why the bone reaches the same density at 200
Am from the implants containing the three highest zoledr-
onate concentration. It also explains why the implants with
the two lowest zoledronate content (0.2 and 0 Ag) are lower
by 17% and by 45%, respectively, compared to the highest
density. These observations constitute an indirect evidence
of the release and delivery of zoledronate in a local region
around the HA/zoledronate-coated implants, although it
does not rule out the possibility that the zoledronate
transport is also carried out by the osteoclasts having
ingested the bisphosphonate.
Since the peri-implant bone density and the maximum
pullout force are influenced by the presence of zoledronate,
a correlation may exist between bone density and mechan-
ical stability. In fact, the correlation between the pullout
force and the density of the bone taken at a distance of 3 Am
from the implant’s surface is strong (R2 = 0.87). Interest-
ingly, when the bone density is taken at a greater distance
from the implant, the correlation decreases. At 20 Am, the
correlation factor decreases to 0.77 and progressively to
0.49 at 58 Am. When the bone density used for the
correlation calculation is taken at 200 Am, the correlation
factor is as low as 0.02. Thus, the first 20 Am are of
uttermost importance for the mechanical fixation of an
implant. Thereby the approach of increasing the peri-
implant density by a local drug delivery becomes even
more justified.
In most in vivo studies, the effect of bisphosphonates on
the histomorphometry of bone was an increase in trabecularnumber and thickness and a decrease of trabecular
separation [18,24,30]. In our study, none of those param-
eters seems to be altered by the presence of zoledronate. The
parameters Tm.Tm/TSL, Nd.Tm/TSL, Nd.Nd/TSL, and
TSL illustrate a narrowing of the network structure of
trabecular bone. These differences may be explained by the
different delivery methods. In the other studies, the
bisphosphonate arrives through the blood into the bone,
where it is distributed in the whole bone. Therefore, the drug
will affect the bone density and the bone structure as a
whole, affecting globally the biomechanical properties of
the bone. In our case, the bisphosphonate is directly brought
into the bone. Moreover, only a local region around the
implant will be exposed to the drug. Thus, only the peri-
implant bone density and structure will be affected leading
to a different biomechanical situation than in the case where
the bisphosphonate was used in a systemic way. Those
different biomechanical situation could be one explanation
of the differences in bone structure observed after systemic
or local bisphosphonate treatment. The zoledronate-related
changes in the bone structure also strongly influenced the
mechanical fixation of the implant. Indeed, the correlation
between the histomorphometric parameters Tm.Tm/TSL,
Nd.Tm/TSL, Nd.Nd/TSL, and TSL was strong. Therefore,
the narrowing of the weaved structure of bone trabeculae
enhanced the fixation of the implant.
The pH of the zoledronate solution (used as sodium salt)
was 6.8. Since the sodium salt is used, the pH is
independent of the zoledronate concentration. The surface
state of the HA has been checked by SEM, but no change
due to Zoledronate grafting was observed (data not shown).
The zoledronate was grafted by ion exchange with the
phosphate ions from the HA [20]. Based on this data, the
HA coating does not become saturated with bisphosphonate,
but an equilibrium is created between the phosphate groups
and the bisphosphonate groups. This explains the zoledro-
nate solution concentration effect. The differences in
zoledronate content of the coating, although the different
bisphosphonate solutions had several orders of magnitude,
can be explained by the fact that the ion exchange reaction is
an equilibrium between the bisphosphonate groups and the
phosphate groups in the coating.
Bisphosphonate, by affecting bone remodeling, could
also block the bone repair process. The drug at too high
concentrations could then have detrimental effects on the
fixation of the implant over longer periods of time. Indeed,
conflicting studies have reported that the use of bisphosph-
onate can interact with the repair of cracks and fractures,
while other studies were unable to demonstrate this
phenomena [17,21–23]. Specifically for the zoledronate, it
has been shown that aminobisphosphonate (like zoledro-
nate), due to the lower dosing, will not impair with the
fractures and cracks repair [4]. A very encouraging result
was obtained in a 7-year follow-up studies of alendronate
treatment in osteoporotic women which did not show any
adverse effects [36]. Long-term results for implants used as
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implant stability. Indeed, the present study was designed as
proof of concept for increasing implant stability with a drug
delivery system. The positive results obtained allow us to
design now a long-term study.Conclusion
In this study, we were able to demonstrate the effective-
ness of the concept of using a local bisphosphonate delivery
from a calcium phosphate coating in order to increase the
mechanical fixation of an orthopedic implant. Moreover, we
showed that the increase in peri-implant bone density is
zoledronate concentration-dependent. The zoledronate
release from the coating positively influences the structure
of the trabecular bone and therefore the mechanical stability
of the implant. We showed that the mechanical stability of
an implant is correlated to the 20 Am of bone around to the
implant, advocating then in favor of a local delivery system.
A long-term in vivo animal should then be performed to
confirm these results which would open the way of an easy
transformation of currently existing HA-coated implants. By
grafting zoledronate onto the coating, their service life in
patients could be increased.Acknowledgments
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